A correlation analysis of autonomic nervous function and cognitive function in Parkinson's disease

Xiyu LI, Xiaoqiao REN, Jia LIU, Tian XU, Zihan WANG, Yanmei LIU, Shuai LIU, Zhihong SHI

Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 298-304.

PDF(885 KB)
Home Journals Chinese Journal of Alzheimer's Disease and Related Disorders
Chinese Journal of Alzheimer's Disease and Related Disorders

Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders      Editor in chief: Jun WANG

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(885 KB)
Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 298-304. DOI: 10.3969/j.issn.2096-5516.2026.05.002
Research Articles

A correlation analysis of autonomic nervous function and cognitive function in Parkinson's disease

Author information +
History +

Abstract

Objective: To evaluate the correlation between autonomic dysfunction and cognitive function in patients with Parkinson's disease (PD). Methods: This study included 221 PD patients who visited the Movement Disorders Outpatient Department of Tianjin Huanhu Hospital from January 2023 to December 2024. All patients were evaluated using the Autonomic Neurological Assessment Scale (SCOPA-AUT) and were divided into two groups based on their SCOPA-AUT scores: group with high autonomic nervous symptom burden(H-ANS)(n=120) and low autonomic nervous symptom burden(L-ANS)(n=101). The differences between the H-ANS group and the L-ANS group using Pearson chi square test or non-parametric Mann Whitney U test were compared. Statistical analysis was conducted using Spearman correlation analysis and multiple linear regression. Results: Compared with patients with PD in the L-ANS group, those in the H-ANS group had a higher age (68.62±7.04 vs. 64.67±7.74, P<0.01), a longer duration of illness (5.13±5.10 vs. 3.94±3.10, P=0.043), and a later onset age (63.37±8.70 vs. 60.57±7.82, P=0.013). In the high-age group (age > 68 years) of Parkinson's disease (PD) patients, the H-ANS group had higher H&Y scores (3 vs. 2.5, P < 0.05), higher Unified Parkinson's Disease Rating Scale-III (UPDRS-III) scores (36.5 vs. 27.5, P < 0.05), and lower Montreal Cognitive Assessment (MoCA) scores (19 vs. 20, P = 0.047) compared to the L-ANS group. In the younger age group (aged ≤68 years), patients with PD in the H-ANS group had higher H&Y scores (2.5 vs. 2, P<0.05) and UPDRS-III scores (36.5 vs. 25, P<0.05) compared to those in the L-ANS group. However, there was no significant difference in cognitive scores between the two groups (P>0.05). In patients with PD in the older age group, there was a significant negative correlation between the total score of MoCA and digestive system disorders (r=-0.252, P=0.012). After controlling for confounding factors, the number of years of education showed an independent positive correlation with the total MoCA score (β=0.379, P<0.001), while the UPDRS-III score demonstrated an independent negative correlation with the total MoCA score (β=-0.319, P=0.005). However, various dimensions of autonomic nervous system function, including the digestive, urinary, cardiovascular, thermoregulatory, and pupillary regulatory systems, did not show any independent significant association with the total MoCA score (all P>0.05). Conclusion: In elderly patients with PD, autonomic dysfunction was significantly correlated with motor and cognitive functions. Further univariate analysis demonstrated that gastrointestinal dysfunction was significantly associated with cognitive decline. In younger patients with PD, the correlation between autonomic dysfunction and cognitive function is not obvious.

Key words

Parkinson’s disease / Autonomic dysfunction / Cognitive function / Correlation analysis

Cite this article

Download Citations
Xiyu LI , Xiaoqiao REN , Jia LIU , et al . A correlation analysis of autonomic nervous function and cognitive function in Parkinson's disease[J]. Chinese Journal of Alzheimer's Disease and Related Disorders. 2026, 9(5): 298-304 https://doi.org/10.3969/j.issn.2096-5516.2026.05.002

References

[1]
Schapira A H V, Chaudhuri K R, Jenner P. Non-motor features of Parkinson disease[J]. Nat Rev Neurosci, 2017, 18(8): 509.
[2]
Berg D, Postuma R B, Adler C H, et al. MDS research criteria for prodromal Parkinson's disease[J]. Mov Disord, 2015, 30(12): 1600-1611.
[3]
Fereshtehnejad S M, Yao C, Pelletier A, et al. Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: Aprospective study[J]. Brain, 2019, 142(7): 2051-2067.
[4]
Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment[J]. Neurobiol Dis, 2020, 134: 104700.
[5]
Pfeiffer R F. Autonomic Dysfunction in Parkinson's Disease[J]. Neurotherapeutics, 2020, 17(4): 1464-1479.
[6]
Leclair-Visonneau L, Magy L, Volteau C, et al. Heterogeneous pattern of autonomic dysfunction in Parkinson's disease[J]. J Neurol, 2018, 265(4): 933-941.
[7]
Sklerov M, Browner N, Dayan E, et al. Autonomic and Depression Symptoms in Parkinson's Disease: Clinical Evidence for Overlapping Physiology[J]. J Parkinsons Dis, 2022, 12(3): 1059-1067.
[8]
Ledda C, Montanaro E, Imbalzano G, et al. Burden of caregiving for cardiovascular dysautonomia in Parkinson's disease[J]. Clin Auton Res, 2022, 32(6): 455-461.
[9]
Arnao V, Cinturino A, Valentino F, et al. In patient's with Parkinson disease, autonomic symptoms are frequent and associated with other non-motor symptoms[J]. Clin Auton Res, 2015, 25(5): 301-307.
[10]
Merola A, Romagnolo A, Rosso M, et al. Autonomic dysfunction in Parkinson's disease: A prospective cohort study[J]. Mov Disord, 2018, 33(3): 391-397.
[11]
Longardner K, Merola A, Litvan I, et al. Differential impact of individual autonomic domains on clinical outcomes in Parkinson's disease[J]. J Neurol, 2022, 269(10): 5510-5520.
[12]
Stewart C B, Ledingham D, Foster V K, et al. The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study[J]. Front Neurol, 2023, 14: 1155669.
[13]
中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4):268-271.
[14]
Leite Silva A B R, Goncalves De Oliveira R W, Diogenes G P, et al. Premotor, nonmotor and motor symptoms of Parkinson's Disease: A new clinical state of the art[J]. Ageing Res Rev, 2023, 84: 101834.
[15]
Van Dijk J G, Haan J, Zwinderman K, et al. Autonomic nervous system dysfunction in Parkinson's disease: Relationships with age, medication, duration, and severity[J]. J Neurol Neurosurg Psychiatry, 1993, 56(10): 1090-1095.
[16]
De Pablo-Fernandez E, Tur C, Revesz T, et al. Association of autonomic dysfunction with disease progression and survival in Parkinson disease[J]. JAMA Neurol, 2017, 74(8): 970-976.
[17]
Fujita H, Ogaki K, Shiina T, et al. Impact of autonomic symptoms on the clinical course of Parkinson's disease[J]. Neurol Sci, 2024, 45(8): 3799-3807.
[18]
Bansal N R, Paul B S, Paul G, et al. Gender differences and impact of autonomic disturbance on fatigue and quality of life in Parkinson's disease[J]. Neurol India, 2022, 70(1): 203-208.
[19]
Morimoto R, Iijima M, Okuma Y, et al. Associations between non-motor symptoms and patient characteristics in Parkinson's disease: a multicenter cross-sectional study[J]. Front Aging Neurosci, 2023, 15: 1252596.
[20]
Wolff M, Halassa M M. The mediodorsal thalamus in executive control[J]. Neuron, 2024, 112(6): 893-908.
[21]
Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease[J]. Nat Rev Neurol, 2017, 13(4): 217-231.
[22]
Salim S, Ahmad F, Banu A, et al. Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment[J]. J Adv Res, 2023, 50: 83-105.
[23]
Qu S, Yu Z, Zhou Y, et al. Gut microbiota modulates neurotransmitter and gut-brain signaling[J]. Microbiol Res, 2024, 287: 127858.
[24]
Clasen F, Yildirim S, Arikan M, et al. Microbiome signatures of virulence in the oral-gut-brain axis influence Parkinson's disease and cognitive decline pathophysiology[J]. Gut Microbes, 2025, 17(1): 2506843.
[25]
Zeng T, Lin C, Deng Y, et al. Effect of BF839 + earthworm protein supplement on motor and some non-motor symptoms of Parkinson's disease: A randomized clinical trial[J]. Front Neurol, 2024, 15: 1371791.
[26]
Liu T, Wu H, Wei J. Beyond the brain: Exploring the multi-organ axes in Parkinson's disease pathogenesis[J]. J Adv Res, 2026, 80: 451-474.
[27]
Sakakibara R, Tateno F, Nagao T, et al. Bladder function of patients with Parkinson's disease[J]. Int J Urol, 2014, 21(7): 638-646.
[28]
Fowler C J, Griffiths D J. A decade of functional brain imaging applied to bladder control[J]. Neurourol Urodyn, 2010, 29(1): 49-55.
[29]
Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson's disease: A review[J]. Parkinsonism Relat Disord, 2009, 15(2): 81-87.
[30]
Tkaczynska Z, Pilotto A, Becker S, et al. Association between cognitive impairment and urinary dysfunction in Parkinson's disease[J]. J Neural Transm (Vienna), 2017, 124(5): 543-550.

Footnotes

利益冲突声明 所有作者在本研究者均不存在任何利益冲突。

PDF(885 KB)

Accesses

Citation

Detail

Sections
Recommended

/

〈 〉